BioCentury | Dec 20, 2010
Company News

Inimex, SARomics Biostructures AB, Vectron Biosolutions A/S deal

...an undisclosed milestone payment from Inimex under a 2009 deal to solve the structure of Inimex's...
...peptide that has completed Phase I testing hospital bacterial infections. Further terms were not disclosed. Inimex Pharmaceuticals Inc....
BioCentury | Dec 7, 2009
Company News

Inimex management update

Inimex Pharmaceuticals Inc. , Burnaby, B.C. Business: Infectious, Autoimmune Hired: Michael Abrams as president and CEO, formerly president and CEO of AnorMed Inc. (now a part of Genzyme Corp. ); he replaces John North, who will...
BioCentury | Nov 24, 2009
Company News

Inimex names Abrams CEO

...Infectious disease and autoimmune company Inimex Pharmaceuticals Inc . (Burnaby, B.C.) hired Michael Abrams as president...
BioCentury | Jul 30, 2009
Cover Story

Nanoparticles vs. bacteria

...known susceptibility to hemolysis by cationic peptides," said John North, president and CEO of Inimex Pharmaceuticals Inc. Inimex...
...can be shortened without impairing its in vivo antimicrobial activity," said Bob Hancock, cofounder of Inimex...
...Published online July 30, 2009 Companies and Institutions Mentioned Ceragenix Pharmaceuticals Inc. (OTCBB:CGXP), Denver, Colo. Inimex Pharmaceuticals Inc....
BioCentury | May 4, 2009
Clinical News

IMX942: Phase I started

...double-blind, placebo-controlled, single and multiple ascending-dose Phase I trial to evaluate IMX942 in 78 patients. Inimex Pharmaceuticals Inc....
BioCentury | Oct 9, 2008
Cover Story

Blocking Bacterial Division

...perspective that asks for noninferiority to already approved drugs," he said. Hancock is cofounder of Inimex Pharmaceuticals Inc....
...and Institutions Mentioned Cubist Pharmaceuticals Inc. (NASDAQ:CBST), Lexington, Mass. Enanta Pharmaceuticals Inc. , Watertown, Mass. Inimex Pharmaceuticals Inc....
BioCentury | Jun 9, 2008
Company News

Inimex board of directors update

Inimex Pharmaceuticals Inc. , Vancouver, B.C. Business: Infectious Appointed: Gerald Chan, co-founder of the Morningside Group WIR Staff Infectious...
BioCentury | Jun 3, 2008
Financial News

Inimex raises $22 million

...JovInvestment Management's Canadian Medical Discovery Fund; and GrowthWorks Capital's Working Opportunity Fund in the round. Inimex's...
...in mid-2009 to control bacterial infections in cancer patients undergoing chemotherapy. Morningside's Gerald Chan joined Inimex's...
BioCentury | Apr 2, 2007
Clinical News

Inimex preclinical data

...levels of monocytes chemokines and reduced proinflammatory cytokine responses. Data were published in Nature Biotechnology. Inimex Pharmaceuticals Inc....
BioCentury | Nov 13, 2006
Company News

Inimex management update

Inimex Pharmaceuticals Inc. , Vancouver, B.C. Business: Infectious Hired: K. Jeffry Wilson as VP of product development, formerly EVP of quality assurance and regulatory affairs at AppTec Laboratory Services Inc. WIR Staff...
Items per page:
1 - 10 of 16
BioCentury | Dec 20, 2010
Company News

Inimex, SARomics Biostructures AB, Vectron Biosolutions A/S deal

...an undisclosed milestone payment from Inimex under a 2009 deal to solve the structure of Inimex's...
...peptide that has completed Phase I testing hospital bacterial infections. Further terms were not disclosed. Inimex Pharmaceuticals Inc....
BioCentury | Dec 7, 2009
Company News

Inimex management update

Inimex Pharmaceuticals Inc. , Burnaby, B.C. Business: Infectious, Autoimmune Hired: Michael Abrams as president and CEO, formerly president and CEO of AnorMed Inc. (now a part of Genzyme Corp. ); he replaces John North, who will...
BioCentury | Nov 24, 2009
Company News

Inimex names Abrams CEO

...Infectious disease and autoimmune company Inimex Pharmaceuticals Inc . (Burnaby, B.C.) hired Michael Abrams as president...
BioCentury | Jul 30, 2009
Cover Story

Nanoparticles vs. bacteria

...known susceptibility to hemolysis by cationic peptides," said John North, president and CEO of Inimex Pharmaceuticals Inc. Inimex...
...can be shortened without impairing its in vivo antimicrobial activity," said Bob Hancock, cofounder of Inimex...
...Published online July 30, 2009 Companies and Institutions Mentioned Ceragenix Pharmaceuticals Inc. (OTCBB:CGXP), Denver, Colo. Inimex Pharmaceuticals Inc....
BioCentury | May 4, 2009
Clinical News

IMX942: Phase I started

...double-blind, placebo-controlled, single and multiple ascending-dose Phase I trial to evaluate IMX942 in 78 patients. Inimex Pharmaceuticals Inc....
BioCentury | Oct 9, 2008
Cover Story

Blocking Bacterial Division

...perspective that asks for noninferiority to already approved drugs," he said. Hancock is cofounder of Inimex Pharmaceuticals Inc....
...and Institutions Mentioned Cubist Pharmaceuticals Inc. (NASDAQ:CBST), Lexington, Mass. Enanta Pharmaceuticals Inc. , Watertown, Mass. Inimex Pharmaceuticals Inc....
BioCentury | Jun 9, 2008
Company News

Inimex board of directors update

Inimex Pharmaceuticals Inc. , Vancouver, B.C. Business: Infectious Appointed: Gerald Chan, co-founder of the Morningside Group WIR Staff Infectious...
BioCentury | Jun 3, 2008
Financial News

Inimex raises $22 million

...JovInvestment Management's Canadian Medical Discovery Fund; and GrowthWorks Capital's Working Opportunity Fund in the round. Inimex's...
...in mid-2009 to control bacterial infections in cancer patients undergoing chemotherapy. Morningside's Gerald Chan joined Inimex's...
BioCentury | Apr 2, 2007
Clinical News

Inimex preclinical data

...levels of monocytes chemokines and reduced proinflammatory cytokine responses. Data were published in Nature Biotechnology. Inimex Pharmaceuticals Inc....
BioCentury | Nov 13, 2006
Company News

Inimex management update

Inimex Pharmaceuticals Inc. , Vancouver, B.C. Business: Infectious Hired: K. Jeffry Wilson as VP of product development, formerly EVP of quality assurance and regulatory affairs at AppTec Laboratory Services Inc. WIR Staff...
Items per page:
1 - 10 of 16